{"nctId":"NCT01026220","briefTitle":"Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma","startDateStruct":{"date":"2009-12-07","type":"ACTUAL"},"conditions":["Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma","Stage III Childhood Hodgkin Lymphoma","Stage IV Childhood Hodgkin Lymphoma"],"count":166,"armGroups":[{"label":"Regimen I (consolidation therapy)","type":"EXPERIMENTAL","interventionNames":["Biological: bleomycin sulfate","Drug: doxorubicin hydrochloride","Drug: liposomal vincristine sulfate","Drug: cyclophosphamide","Drug: etoposide phosphate","Drug: prednisone","Biological: filgrastim"]},{"label":"Regimen II (consolidation therapy)","type":"EXPERIMENTAL","interventionNames":["Biological: bleomycin sulfate","Drug: doxorubicin hydrochloride","Drug: liposomal vincristine sulfate","Drug: vinorelbine tartrate","Drug: cyclophosphamide","Drug: etoposide phosphate","Drug: prednisone","Biological: filgrastim","Drug: ifosfamide"]},{"label":"Induction: all patient","type":"EXPERIMENTAL","interventionNames":["Drug: doxorubicin hydrochloride","Drug: liposomal vincristine sulfate","Drug: cyclophosphamide","Drug: etoposide phosphate","Drug: prednisone","Biological: filgrastim"]}],"interventions":[{"name":"bleomycin sulfate","otherNames":["Blenoxane","BLEO","BLM"]},{"name":"doxorubicin hydrochloride","otherNames":["ADM","ADR","Adria","Adriamycin PFS","Adriamycin RDF"]},{"name":"liposomal vincristine sulfate","otherNames":["liposomal vincristine","Marqibo","vincristine liposomal","vincristine sulfate liposome injection"]},{"name":"vinorelbine tartrate","otherNames":["Eunades","navelbine ditartrate","NVB","VNB"]},{"name":"cyclophosphamide","otherNames":["CPM","CTX","Cytoxan","Endoxan","Endoxana"]},{"name":"etoposide phosphate","otherNames":["ETOP","Etopophos"]},{"name":"prednisone","otherNames":["DeCortin","Deltra"]},{"name":"filgrastim","otherNames":["G-CSF","Neupogen"]},{"name":"ifosfamide","otherNames":["Cyfos","Holoxan","IFF","IFX","IPP"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically confirmed newly diagnosed Hodgkin lymphoma (HL) meeting one of the following criteria:\n\n  * Classical disease\n  * Nodular lymphocyte-predominant disease\n* Stage III or IV disease with B symptoms, as defined by ≥ 1 of the following:\n\n  * Unexplained weight loss \\> 10% within the past 6 months\n  * Unexplained recurrent fever \\> 38°C within the past month\n  * Recurrent drenching night sweats within the past month\n* Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR maximum serum creatinine based on age/gender as follows:\n\n  * 0.4 mg/dL (1 to 5 months)\n  * 0.5 mg/dL (6 to 11 months)\n  * 0.6 mg/dL (12 to 23 months)\n  * 0.8 mg/dL (2 to 5 years)\n  * 1 mg/dL (6 to 9 years)\n  * 1.2 mg/dL (10 to 12 years)\n  * 1.5 mg/dL (males) or 1.4 mg/dL (females) (13 to 15 years)\n  * 1.7 mg/dL (males) or 1.4 mg/dL (females) (≥ 16 years)\n* Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age\n* AST or ALT \\< 2.5 times ULN for age\n* Shortening fraction ≥ 27% by ECHO OR ejection fraction ≥ 50% by MUGA (unless due to large mediastinal mass from HL)\n* FEV\\_1/FVC \\> 60% by pulmonary function tests (PFT) (unless due to large mediastinal mass fromHL)\n\n  * For children who are unable to cooperate for PFTs, the criteria are:\n\n    * No evidence of dyspnea at rest\n    * No exercise intolerance\n    * Pulse oximetry \\> 92% on room air\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No pathologic prolongation of QTc interval (\\> 450 milliseconds) on 12-lead ECG\n* No prior chemotherapy, biological response modifiers (e.g., monoclonal antibody therapy), or radiotherapy\n* At least 28 days since prior corticosteroids except for emergent treatment for respiratory distress or spinal cord compression, or for treatment of allergy to contrast agent required for CT scan\n* No other concurrent cancer chemotherapy or immunomodulating agents (including steroids)\n\n  * Concurrent corticosteroid therapy as treatment or prophylaxis for anaphylactic reactions allowed\n* No concurrent pegfilgrastim","healthyVolunteers":false,"sex":"ALL","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Second-event-free Survival","description":"Second event here is defined as any relapse/progression of Hodgkin Lymphoma (HL) or a previously reported second malignant neoplasm (SMN), a new SMN, or death after a first event which can be relapse/progression of HL, SMN, biopsy-proven HL following completion of Consolidation for Slow Early Response (SER) patient, positive bilateral bone marrow biopsy following completion of Consolidation for Stage IV patient, or death. If death occurs as the 1st event, it also counts as the 2nd event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":null}]}]}]},{"type":"PRIMARY","title":"Safety Analysis and Monitoring of Toxic Death","description":"The primary endpoint for safety analysis and monitoring is toxic death, which is death primarily attributable to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Event Free Survival","description":"Survival from enrollment to first event: relapse/progression, second malignancy, or death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":null}]}]}]},{"type":"SECONDARY","title":"Second-event-free Survival","description":"Second event here is defined as any relapse/progression of Hodgkin Lymphoma (HL) or a previously reported second malignant neoplasm (SMN), a new SMN, or death after a first event which can be relapse/progression of HL, SMN, biopsy-proven HL following completion of Consolidation for Slow Early Response (SER) patient, positive bilateral bone marrow biopsy following completion of Consolidation for Stage IV patient, or death. If death occurs as the 1st event, it also counts as the 2nd event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":null},{"groupId":"OG001","value":"0.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival for Rapid Early Response (RER) Positron Emission Tomography(PET)-1 Positive, RER PET-1 Negative","description":"To investigate whether very early response assessment measured by Fluorodeoxyglucose-PET after 1 cycle of chemotherapy identifies a subject cohort that can be studied in future trials and that is distinguishable from currently defined RER after 2 cycles.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":null},{"groupId":"OG001","value":"0.82","spread":null},{"groupId":"OG002","value":"0.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Relapse-free Survival","description":"A description, survival to relapse, of patterns of relapse after Doxorubicin, Bleomycin, Vincristine, Etoposide - Prednisone, Cyclophosphamide (ABVE-PC) and risk-adapted radiotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null},{"groupId":"OG001","value":"0.83","spread":null},{"groupId":"OG002","value":"0.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Event Free Survival","description":"Survival from enrollment to first event: relapse/progression, second malignancy, or death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null},{"groupId":"OG001","value":"0.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Grade 3 and 4 Non-hematologic Toxicities During Protocol Therapy","description":"The number of patients that experience Common Terminology Criteria (CTC) Version 4 grade 3 or higher non-hematologic toxicity at any time during protocol therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Survival from enrollment to death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"0.97","spread":null},{"groupId":"OG002","value":"0.97","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":165},"commonTop":["Febrile neutropenia","Mucositis oral","Infections and infestations - Other, specify","Fever","Alanine aminotransferase increased"]}}}